Biomarker-guided treatment of congestive heart failure

Congestive Heart Failure

Volumn 16, Issue SUPPL. 1, 2010, Pages

  Xue, Yang ^a,b   Chan, Jeffrey ^a   Sakariya, Sonal ^a   Maisel, Alan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COPEPTIN; HORMONE PRECURSOR; MIDREGIONAL PROATRIAL NATRIURETIC FACTOR; NEOPTERIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROADRENOMEDULLIN; TROPONIN; UNCLASSIFIED DRUG;

COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REPRODUCIBILITY; REVIEW; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; PATIENT CARE PLANNING; PEPTIDE FRAGMENTS; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77955154821     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00169.x     Document Type: Review

References (23)

1. Heart Disease and Stroke Statistics: 2005 Update 2005, Dallas, TX, American Heart Association
2. Jhund PS, Macintyre K, Simpson CR. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009, 119(4):515-523. Epub 2009 Jan 19
3. Davis M, Espiner E, Richards G. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 1994, 343:440-444.
4. Richards AM, Crozier IG, Yandle TG. Brain natriuretic factor: regional plasma concentrations and correlations with hemodynamic state in cardiac disease. Br Heart J 1993, 69:414-417.
5. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993, 132:1961-1970.
6. Anand IS, Fisher LD, Chiang Y-T. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003, 107:1278-1283.
7. Troughton RW, Richards AM, Yandle TG. The effects of medications on circulating levels of cardiac natriuretic peptides. Ann Med 2007, 39:242-260.
8. Fruhwald FM, Fahrleitner-Pammer A, Berger R. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 2007, 28:1592-1597.
9. Ikeda T, Matsuda K, Itoh H. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 1997, 133:307-314.
10. Yoshimura M, Yasue H, Okumura K. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993, 87(2):464-469.
11. Yasue H, Yoshimura M, Sumida H. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994, 90(1):195-203.
12. Lang CC, Choy AM, Turner K. The effect of intravenous saline loading on plasma levels of brain natriuretic peptide in man. J Hypertens 1993, 11(7):737-741.
13. Haug C, Metzele A, Kochs M. Plasma brain natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol 1993, 16(7):553-557.
14. Massie B, Ports T, Chatterjee K. Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. Circulation 1981, 63(2):269-278.
15. Yamamoto K, Burnet JC, Jougasaki M. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996, 28(6):988-994.
16. Troughton RW, Frampton CM, Yandle TG. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000, 355:1126-1130.
17. Shah MR. STARBRITE: a randomized pilot trial of BNP-guided therapy in patients with advanced heart failure. Circulation 2006, 114(II):528.
18. Lainchbury JG, Troughton RW, Strangman KM. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009, 55(1):53-60.
19. Pfisterer M, Buser P, Rickli H. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009, 301(4):383-392.
20. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987, 316:1429.
21. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991, 325:293-302.
22. Doughty R, Yee T, Sharpe N, MacMahon S. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988-91. N Z Med J. 1995, 108:473-475.
23. Jourdain P, Jondeau G, Funck F. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007, 49(16):1733-1739.